Drug: Blinatumomab (Blincyto, Amgen)
Status: Granted priority review to expand the indication for the treatment of all patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Significant Information:
- Based on data from the Phase III TOWER study investigating the efficacy of blinatumomab versus standard-of-care (SOC) chemotherapy in 405 adult patients with Philadelphia chromosome–negative (Ph–) relapsed or refractory B-cell precursor